In a BLT humanized mouse model, combining anti-PD-L1, anti-CTLA-4, and anti-IFN-β reduced tumor growth by 96.2%, surpassing PD-L1/CTLA-4 inhibition alone (82.9%), by decreasing T-cell exhaustion markers [54]. The gene discussed is CTLA4; the disease is neoplasm.